According to World Health Organization (WHO), in December 2021, 273 million cases are diagnosed and approximately 5.3 million deaths have been reported, globally, due to COVID-19.
Recent advancements in dPCR technology have led to increased sensitivity and accuracy, enabling the detection of rare genetic variants and low-level pathogens. This has important implications for cancer diagnosis and monitoring, infectious disease detection, and other areas of research.
Growing demand for precision medicine
Digital PCR enables the detection and quantification of rare genetic mutations with high accuracy, which is important for the development of precision medicine. The increasing demand for personalized medicine is expected to drive the demand for digital PCR.
Rising Adoption of Digital PCR Devices
In 2022, a total of 96,091,120 COVID-19 Cases are counted in the United States.
Growing adoption of non-invasive prenatal testing
Non-invasive prenatal testing (NIPT) is becoming increasingly popular, as it enables the detection of fetal genetic abnormalities without the need for invasive procedures. Digital PCR is a key technology used in NIPT, and the growing adoption of NIPT is expected to drive the demand for digital PCR.
Rising Fund for Research and Development Activities in the Digital PCR
Due to COVID19 pandemic, an unexpected demand was increased for Digital PCR in the healthcare and research institute sector. The pandemic has played an important role to enhance the digital PCR market growth. Prevalence of infectious diseases like cancer has also increasedwhich accounts for the need for the diagnosis and detection of the disease. For this reason, funding in the research and development sector has also increased. Increased funding for R&D activities that include the use of digital PCR and Chip based PCR for different purposes, is expected to increase its use and open up new opportunities for global market expansion during the forecast period.
Recent Development
- Launched in 2021 by QIAGEN, this digital PCR system is designed for ultra-sensitive and accurate detection and quantification of target DNA and RNA sequences. It has a high dynamic range and can detect as few as two copies of a target sequence.
- Launched in 2020 by JN Medsys, this digital PCR system is designed for the detection of SARS-CoV-2 virus in clinical samples. It uses a multiplex digital PCR assay to simultaneously detect two viral genes with high sensitivity and specificity.
- Launched in 2019 by RainDance Technologies, this digital PCR system is designed for ultra-sensitive detection and quantification of nucleic acid targets. It uses microfluidic droplet technology to partition each sample into millions of droplets, each of which undergoes digital PCR amplification to detect and quantify target molecules.
Download Free Sample Report
Market Segmentation
In terms of country, the United States region is dominating the overall globe in digital PCR market. According to Worldometer, as of December 26, 2022 around 102,236,095 confirmed COVID-19 cases have been reported in the United States. This can be ascribed to the increasing cost-effective COVID-19 testing technology in the healthcare sector.
Market Players
Bio-Rad Laboratories, Inc., Fluidigm Corporation, F. Hoffmann-La Roche AG, Merck KGaA, QIAGEN N.V., Thermo Fisher Scientific Inc., Genetron Holdings Limited, Naveris, Inc., SAGA Diagnostics, Precigenome LLC
Attribute | Details |
Base Year | 2022 |
Historic Data | 2018 – 2021 |
Estimated Year | 2023 |
Forecast Period | 2024 – 2028 |
Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
Report coverage | Revenue forecast, volume forecast, company share, competitive landscape, growth factors, and trends |
Segments covered | By Type By Component By Application By End User By Region |
Regional scope | North America; Europe; Asia Pacific; South America; Middle East & Africa |
Country scope | United States; Mexico; Canada; France; Germany; United Kingdom; Italy; Spain; China; India; South Korea; Japan; Australia; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE; Egypt; Turkey |
Key companies profiled | Bio-Rad Laboratories, Inc., Fluidigm Corporation, F. Hoffmann-La Roche AG, Merck KGaA, QIAGEN N.V., Thermo Fisher Scientific Inc., Genetron Holdings Limited, Naveris, Inc., SAGA Diagnostics, Precigenome LLC |
Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |